How Semaglutide Is Made: Lab to Injection
The science and engineering behind manufacturing the world's most prescribed weight loss medication.
Semaglutide is a marvel of pharmaceutical engineering -- a 31-amino-acid peptide modified to survive in the human body for a week instead of the 2 minutes that natural GLP-1 lasts. Understanding how it is made helps explain both why brand-name versions are expensive and why compounded versions can deliver the same molecule at lower cost.
Step 1: Molecular Design
Semaglutide is based on native human GLP-1(7-37) with three key modifications. First, an amino acid substitution at position 8 (alanine to alpha-aminoisobutyric acid) makes it resistant to DPP-4 enzyme degradation. Second, an amino acid substitution at position 34 (lysine to arginine) prevents fatty acid attachment at the wrong site. Third, a C18 fatty diacid chain is attached at position 26 via a linker, enabling reversible albumin binding. These modifications extend the half-life from 2 minutes to approximately 7 days -- making once-weekly dosing possible.
Step 2: Peptide Production
Two Production Methods
Recombinant DNA (Novo Nordisk)
- - Gene encoding semaglutide inserted into yeast cells
- - Yeast grown in large fermentation tanks
- - Cells produce the peptide backbone
- - Harvested and chemically modified
- - Higher scale, lower per-unit cost
Solid-Phase Synthesis (Compounding)
- - Amino acids assembled one by one on a resin
- - Automated peptide synthesizer
- - Chemical assembly of exact sequence
- - Cleaved from resin, purified
- - Smaller batches, flexible production
Step 3: Fatty Acid Attachment
After the peptide backbone is produced, the C18 fatty diacid side chain is chemically conjugated to the lysine residue at position 26 through a specific linker. This step is critical -- the fatty acid chain is what gives semaglutide its long duration of action by enabling reversible binding to serum albumin.
Step 4: Purification
The crude semaglutide undergoes multiple rounds of high-performance liquid chromatography (HPLC) to remove impurities, incomplete peptides, and by-products. The final product must meet strict purity standards (typically greater than 98% purity for pharmaceutical grade).
Step 5: Formulation and Fill
Purified semaglutide is dissolved in a sterile buffer solution with stabilizers (typically phosphate buffer with propylene glycol and phenol as preservative). The solution is sterile-filtered and filled into vials or injection pens under aseptic conditions. Every batch undergoes testing for potency, sterility, endotoxin levels, pH, and particulate matter.
Step 6: Quality Testing
Quality Control Tests
- Identity: Confirms the molecule is semaglutide via mass spectrometry
- Potency: Verifies concentration matches label claim
- Purity: HPLC analysis for related substances and degradation products
- Sterility: 14-day incubation test confirms no microbial growth
- Endotoxin: LAL test confirms bacterial endotoxin below limits
- pH and osmolality: Ensures compatibility with subcutaneous injection
Compounded Semaglutide at Trimi
Trimi's compounded semaglutide undergoes the same quality testing standards. Sourced from FDA-registered 503B pharmacies, each batch includes a certificate of analysis documenting potency, sterility, and purity testing. The result is the same semaglutide molecule at $99/month -- a fraction of brand-name cost.
Quality Semaglutide at $99/Month
Same molecule. Third-party tested. FDA-registered pharmacy sourcing.
Get StartedMedical Disclaimer
This article is for educational purposes. Manufacturing details are simplified for general understanding. Specific processes may vary between manufacturers and compounding pharmacies. Always consult your healthcare provider.
More on GLP-1 reference
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).